Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v2.4.0.8
Condensed Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Net (loss) income $ (4,270) $ 1,242
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization 837 577
Realignment accrual accretion 71 71
Stock-based compensation 1,358 1,073
Other changes in assets and liabilities:    
(Increase) decrease in accounts receivable (1,424) 4,584
Decrease (increase) in unbilled costs 1,046 (5,599)
Decrease in other current assets 505 804
Decrease in other long-term assets 138 0
Decrease in accounts payable (295) (241)
Decrease in unearned contract revenue (1,528) (2,532)
(Decrease) increase in accrued salaries and bonus (3,386) 1,903
Decrease in other accrued expenses (570) (1,737)
Decrease in long-term liabilities (770) (719)
Net cash used in operating activities (8,288) (574)
Cash Flows From Investing Activities    
Purchase of property and equipment (860) (956)
Loan to the Diagnostic Company (655) 0
Net cash used in investing activities (1,515) (956)
Cash Flows From Financing Activities    
Payments for Repurchase of Common Stock (215) (230)
Net cash used in financing activities (215) (230)
Net increase (decrease) in cash and cash equivalents (10,018) (1,760)
Cash and cash equivalents – beginning 45,639 52,783
Cash and cash equivalents – ending $ 35,621 $ 51,023